Browse drugs

… cancer. An initial attempt to obtain an insurance approval for pembrolizumab given LS and context of deficient mismatch repair was unsuccess…

…st-line chemotherapy (capecitabine/oxaliplatin) with sequential pembrolizumab. CLDN18.2 expression was assessed by immunohistochemistry, and …

…with NSCLC on ICI monotherapy with nivolumab, pembrolizumab, or atezolizumab, to identify germline variants associated with objective respon…

…nts received ipilimumab and nivolumab (14/31, 45%), followed by pembrolizumab (9/31, 29%), ipilimumab (4/31, 13%), nivolumab (2/31, 6%) and c…

…55 with a larger coverage area than another anti-TIGIT antibody tiragolumab, consistent with surface plasmon resonance analysis, though mou…

…mall cell lung cancer (NSCLC).12 13 However, the superiority of pembrolizumab over chemotherapy in this setting had already been demonstrated…

…le safety and antitumor activity, alone and in combination with pembrolizumab, across heavily pretreated advanced solid tumors in the ARTISTR…

… experienced progressive disease on prior anti-PD-(L)1 therapy. Cavrotolimod, in combination with anti-PD-1 therapy, produced objective resp…

…e authors compared the efficacy of hybrid versus flat dosing of pembrolizumab in advanced non-small cell lung cancer. Although the study show…

…or his comment1 on our article regarding the non-inferiority of pembrolizumab hybrid dosing in patients with advanced non-small cell lung can…